Barinthus Biotherapeutics PLC expected to post a loss of 45 cents a share - Earnings Preview

Reuters10-31

Barinthus Biotherapeutics <a href="https://laohu8.com/S/PLC">PLC</a> <brns.oq> expected to post a loss of 45 cents a share - Earnings Preview </brns.oq>

Barinthus Biotherapeutics PLC BRNS.OQ, BRNS.O is expected to show a fall in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Barinthus Biotherapeutics PLC is for a loss of 45 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Barinthus Biotherapeutics PLC is $5.00, about 74.2% above its last closing price of $1.29

This summary was machine generated October 31 at 14:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579938484?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 22:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579938484","market":"fut","top_or_hot":-1,"title":"Barinthus Biotherapeutics PLC  expected to post a loss of 45 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Barinthus Biotherapeutics <a href=\"https://laohu8.com/S/PLC\">PLC</a> <brns.oq> expected to post a loss of 45 cents a share - Earnings Preview </brns.oq></title></head><body><ul><li><p>Barinthus Biotherapeutics PLC <span>BRNS.OQ</span>, <span>BRNS.O</span> is expected to  show a fall in quarterly revenue when it reports  results on November 4 (estimated) for the period ending September 30 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Barinthus Biotherapeutics PLC is for a loss of 45 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Barinthus Biotherapeutics PLC is $5.00, about 74.2% above its last closing price of $1.29</p></li></ul><p>This summary was machine generated October 31 at 14:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Barinthus Biotherapeutics PLC  expected to post a loss of 45 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBarinthus Biotherapeutics PLC  expected to post a loss of 45 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-31 22:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Barinthus Biotherapeutics <a href=\"https://laohu8.com/S/PLC\">PLC</a> <brns.oq> expected to post a loss of 45 cents a share - Earnings Preview </brns.oq></title></head><body><ul><li><p>Barinthus Biotherapeutics PLC <span>BRNS.OQ</span>, <span>BRNS.O</span> is expected to  show a fall in quarterly revenue when it reports  results on November 4 (estimated) for the period ending September 30 2025</p></li><li></li><li><p>LSEG's mean analyst estimate for Barinthus Biotherapeutics PLC is for a loss of 45 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Barinthus Biotherapeutics PLC is $5.00, about 74.2% above its last closing price of $1.29</p></li></ul><p>This summary was machine generated October 31 at 14:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC1ME:1","article_id":"2579938484","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579938484","pubTimestamp":1761920767,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Barinthus Biotherapeutics PLC  expected to post a loss of45cents a share - Earnings Preview Barinthus Biotherapeutics PLC BRNS.OQ, BRNS.O is expected to  show a fall in quarterly revenue when it repor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","BRNS":"BARINTHUS BIOTHERAPEUTICS PLC ADR EACH REPR 1 ORD SH SPON"},"translate_title":"Barinthus Biotherapeutics PLC预计每股亏损45美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRNS":0.9},"content_text":"Barinthus Biotherapeutics PLC  expected to post a loss of 45 cents a share - Earnings Preview Barinthus Biotherapeutics PLC BRNS.OQ, BRNS.O is expected to  show a fall in quarterly revenue when it reports  results on November 4 (estimated) for the period ending September 30 2025LSEG's mean analyst estimate for Barinthus Biotherapeutics PLC is for a loss of 45 cents per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Barinthus Biotherapeutics PLC is $5.00, about 74.2% above its last closing price of $1.29This summary was machine generated October 31 at 14:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579938484","isCrawlerRequest":true}